Search - tctmd.com

Displaying 21 - 36 of 36

Sort: Relevancy | Date

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

FLOW: Semaglutide Scores Big in Diabetic Patients With CKD

L.A. McKeown

May 24, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

Podcast TCTMD Talking Points

The FIGARO-DKD Trial

November 23, 2022

News Daily News

Lowering BP Boosts CV Health Irrespective of Diabetes: Meta-analysis

Todd Neale

August 02, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2021

Shelley Wood

September 03, 2021

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2021

Shelley Wood

August 02, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

News Conference News AHA 2020

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

Todd Neale

November 16, 2020

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

Advertisement

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

FLOW: Semaglutide Scores Big in Diabetic Patients With CKD

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

The FIGARO-DKD Trial

Lowering BP Boosts CV Health Irrespective of Diabetes: Meta-analysis

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

November 2021 News Roundup

TCTMD’s Top 10 Most Popular Stories for August 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

TCTMD’s Top 10 Most Popular Stories for July 2021

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content